866-997-4948(US-Canada Toll Free)

Multiple Sclerosis Pipeline Review, H1 2013

Published By :

Global Markets Direct

Published Date : Mar 2013

Category :

Oncology

No. of Pages : 605 Pages


Global Markets Directs, \'Multiple Sclerosis Pipeline Review, H1 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Multiple Sclerosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Multiple Sclerosis. 

Multiple Sclerosis Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Multiple Sclerosis.
  • A review of the Multiple Sclerosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Multiple Sclerosis pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Multiple Sclerosis.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Multiple Sclerosis pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2
Introduction 8
Multiple Sclerosis Overview 9
Therapeutics Development 10
Multiple Sclerosis Therapeutics under Development by Companies 12
Multiple Sclerosis Therapeutics under Investigation by Universities/Institutes 25
Late Stage Products 28
Mid Clinical Stage Products 29
Early Clinical Stage Products 30
Discovery and Pre-Clinical Stage Products 31
Multiple Sclerosis Therapeutics Products under Development by Companies 32
Multiple Sclerosis Therapeutics Products under Investigation by Universities/Institutes 47
Companies Involved in Multiple Sclerosis Therapeutics Development 49
Multiple Sclerosis Therapeutics Assessment 182
Drug Profiles 190
Multiple Sclerosis Therapeutics Drug Profile Updates 473
Multiple Sclerosis Therapeutics Discontinued Products 559
Multiple Sclerosis Therapeutics - Dormant Products 562
Multiple Sclerosis Product Development Milestones 571

Appendix 581

List of Table


Number of Products Under Development for Multiple Sclerosis, H1 2013 33
Products under Development for Multiple Sclerosis Comparative Analysis, H1 2013 34
Number of Products under Development by Companies, H1 2013 36
Number of Products under Development by Companies, H1 2013 (Contd..1) 37
Number of Products under Development by Companies, H1 2013 (Contd..2) 38
Number of Products under Development by Companies, H1 2013 (Contd..3) 39
Number of Products under Development by Companies, H1 2013 (Contd..4) 40
Number of Products under Development by Companies, H1 2013 (Contd..5) 41
Number of Products under Development by Companies, H1 2013 (Contd..6) 42
Number of Products under Development by Companies, H1 2013 (Contd..7) 43
Number of Products under Development by Companies, H1 2013 (Contd..8) 44
Number of Products under Development by Companies, H1 2013 (Contd..9) 45
Number of Products under Development by Companies, H1 2013 (Contd..10) 46
Number of Products under Development by Companies, H1 2013 (Contd..11) 47
Number of Products under Investigation by Universities/Institutes, H1 2013 49
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 50
Comparative Analysis by Late Stage Development, H1 2013 51
Comparative Analysis by Mid Clinical Stage Development, H1 2013 52
Comparative Analysis by Early Clinical Stage Development, H1 2013 53
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 54
Products under Development by Companies, H1 2013 55
Products under Development by Companies, H1 2013 (Contd..1) 56
Products under Development by Companies, H1 2013 (Contd..2) 57
Products under Development by Companies, H1 2013 (Contd..3) 58
Products under Development by Companies, H1 2013 (Contd..4) 59
Products under Development by Companies, H1 2013 (Contd..5) 60
Products under Development by Companies, H1 2013 (Contd..6) 61
Products under Development by Companies, H1 2013 (Contd..7) 62
Products under Development by Companies, H1 2013 (Contd..8) 63
Products under Development by Companies, H1 2013 (Contd..9) 64
Products under Development by Companies, H1 2013 (Contd..10) 65
Products under Development by Companies, H1 2013 (Contd..11) 66
Products under Development by Companies, H1 2013 (Contd..12) 67
Products under Development by Companies, H1 2013 (Contd..13) 68
Products under Development by Companies, H1 2013 (Contd..14) 69
Products under Investigation by Universities/Institutes, H1 2013 70
Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 71
Alcon, Inc., H1 2013 72
Baxter International Inc., H1 2013 73
F. Hoffmann-La Roche Ltd., H1 2013 74
Biogen Idec Inc., H1 2013 75
Amgen Inc., H1 2013 76
Eli Lilly and Company, H1 2013 77
Athersys, Inc., H1 2013 78
GlaxoSmithKline plc, H1 2013 79
MedImmune LLC, H1 2013 80
Daiichi Sankyo Company, Ltd, H1 2013 81
Cytokine PharmaSciences, Inc., H1 2013 82
Plexxikon Inc., H1 2013 83
XenoPort, Inc., H1 2013 84
Apitope International NV, H1 2013 85
Novartis AG, H1 2013 86
Isotechnika Pharma Inc., H1 2013 87
Aphios Corporation, H1 2013 88
Acorda Therapeutics, Inc., H1 2013 89
Actelion Ltd, H1 2013 90
Dong-A Pharmaceutical Co., Ltd., H1 2013 91
Elan Corporation, plc, H1 2013 92
Kissei Pharmaceutical Co., Ltd., H1 2013 93
Mitsubishi Tanabe Pharma Corporation, H1 2013 94
Ono Pharmaceutical Co., Ltd., H1 2013 95
Rigel Pharmaceuticals, Inc., H1 2013 96
Teva Pharmaceutical Industries Limited, H1 2013 97
Vertex Pharmaceuticals Incorporated, H1 2013 98
Zydus Cadila Healthcare Limited, H1 2013 99
Genmab A/S, H1 2013 100
Enzon Pharmaceuticals, Inc., H1 2013 101
Hadasit Medical Research Services & Development Ltd, H1 2013 102
Paratek Pharmaceuticals, Inc., H1 2013 103
Celgene Corporation, H1 2013 104
BrainStorm Cell Therapeutics Inc., H1 2013 105
Merck KGaA, H1 2013 106
4SC AG, H1 2013 107
Addex Pharmaceuticals, H1 2013 108
EntreMed, Inc., H1 2013 109
Evotec Aktiengesellschaft, H1 2013 110
Hemispherx Biopharma, Inc., H1 2013 111
Hollis-Eden Pharmaceuticals, Inc., H1 2013 112
Antisense Therapeutics Limited, H1 2013 113
Idera Pharmaceuticals, Inc., H1 2013 114
Karo Bio, H1 2013 115
Almirall, S.A., H1 2013 116
Lpath, Inc., H1 2013 117
Bionomics Limited, H1 2013 118
PROLOR Biotech, Inc., H1 2013 119
MultiCell Technologies, Inc., H1 2013 120
Nutra Pharma Corporation, H1 2013 121
Opexa Therapeutics, Inc., H1 2013 122
Compugen Ltd., H1 2013 123
Critical Outcome Technologies Inc., H1 2013 124
ACADIA Pharmaceuticals Inc., H1 2013 125
Accentia Biopharmaceuticals, Inc., H1 2013 126
Arena Pharmaceuticals, Inc., H1 2013 127
Zenotech Laboratories Limited, H1 2013 128
RegeneRx Biopharmaceuticals, Inc., H1 2013 129
ProMetic Life Sciences Inc., H1 2013 130
MorphoSys AG, H1 2013 131
Cytos Biotechnology AG, H1 2013 132
Pluristem Therapeutics Inc., H1 2013 133
Resverlogix Corp., H1 2013 134
Sareum Holdings plc, H1 2013 135
Santhera Pharmaceuticals Holding AG, H1 2013 136
Transgene Biotek Ltd, H1 2013 137
Stem Cell Therapeutics Corp., H1 2013 138
Morphotek, Inc., H1 2013 139
Digna Biotech, S.L., H1 2013 140
Antitope Ltd., H1 2013 141
Axxam SpA, H1 2013 142
Bayhill Therapeutics, Inc., H1 2013 143
Probiodrug AG, H1 2013 144
Phenex Pharmaceuticals AG, H1 2013 145
Hutchison MediPharma Limited, H1 2013 146
CREABILIS Therapeutics S.r.l., H1 2013 147
Trophos SA, H1 2013 148
Ache Laboratorios Farmaceuticos S/A, H1 2013 149
Artielle ImmunoTherapeutics, Inc., H1 2013 150
Argos Therapeutics, Inc., H1 2013 151
Affectis Pharmaceuticals AG, H1 2013 152
ProtAffin Biotechnologie AG, H1 2013 153
Allozyne, Inc., H1 2013 154
Coronado Biosciences, Inc., H1 2013 155
Q Therapeutics, Inc., H1 2013 156
Catabasis Pharmaceuticals, Inc., H1 2013 157
Five Prime Therapeutics, Inc., H1 2013 158
Vaccinex, Inc., H1 2013 159
Innate Therapeutics Limited, H1 2013 160
Kineta, Inc., H1 2013 161
MSM Protein Technologies, Inc., H1 2013 162
Vascular Biogenics Ltd., H1 2013 163
Xention Limited, H1 2013 164
Txcell SA, H1 2013 165
Phage Biotechnology Corporation, H1 2013 166
Theraclone Sciences, Inc., H1 2013 167
TcL Pharma SAS, H1 2013 168
Biotica Technology Ltd, H1 2013 169
Siena Biotech S.p.A., H1 2013 170
Omeros Corporation, H1 2013 171
Bolder Biotechnology, Inc., H1 2013 172
Aegis Therapeutics, LLC, H1 2013 173
Xencor, Inc., H1 2013 174
Adeona Pharmaceuticals, Inc., H1 2013 175
Trillium Therapeutics Inc., H1 2013 176
Cellceutix Corporation, H1 2013 177
Biovista Inc., H1 2013 178
SanBio, Inc., H1 2013 179
Provid Pharmaceuticals, Inc., H1 2013 180
Epiphany Biosciences, Inc., H1 2013 181
Biokine Therapeutics Ltd., H1 2013 182
KYORIN Pharmaceutical Co., Ltd., H1 2013 183
OncoImmune, Inc., H1 2013 184
to-BBB technologies BV, H1 2013 185
Daval International Ltd., H1 2013 186
Hy BioPharma Inc., H1 2013 187
Medistem, Inc., H1 2013 188
PharmaEssentia Corporation, H1 2013 189
KAHR medical Ltd., H1 2013 190
M\'s Science Corporation, H1 2013 191
Pharnext SAS, H1 2013 192
Ascenion GmbH, H1 2013 193
Amplimmune, Inc., H1 2013 194
Lycera Corp., H1 2013 195
Neuraltus Pharmaceuticals, Inc., H1 2013 196
RhinoCyte, Inc., H1 2013 197
Vakzine Projekt Management GmbH, H1 2013 198
Biopartners Holdings AG, H1 2013 199
Pfenex Inc., H1 2013 200
Cellmid Ltd, H1 2013 201
Varinel, Inc., H1 2013 202
Cognosci, Inc., H1 2013 203
Immune Technologies and Medicine, H1 2013 204
Assessment by Monotherapy Products, H1 2013 205
Assessment by Combination Products, H1 2013 206
Assessment by Stage and Route of Administration, H1 2013 209
Assessment by Stage and Molecule Type, H1 2013 212
Multiple Sclerosis Therapeutics Drug Profile Updates 496
Multiple Sclerosis Therapeutics Discontinued Products 581
Multiple Sclerosis Therapeutics Discontinued Products (Contd..1) 582
Multiple Sclerosis Therapeutics Discontinued Products (Contd..2) 583
Multiple Sclerosis Therapeutics Dormant Products 584
Multiple Sclerosis Therapeutics Dormant Products (Contd..1) 585
Multiple Sclerosis Therapeutics Dormant Products (Contd..2) 586
Multiple Sclerosis Therapeutics Dormant Products (Contd..3) 587
Multiple Sclerosis Therapeutics Dormant Products (Contd..4) 588
Multiple Sclerosis Therapeutics Dormant Products (Contd..5) 589
Multiple Sclerosis Therapeutics Dormant Products (Contd..6) 590
Multiple Sclerosis Therapeutics Dormant Products (Contd..7) 591
Multiple Sclerosis Therapeutics Dormant Products (Contd..8) 592

List of Chart


Number of Products under Development for Multiple Sclerosis, H1 2013 33
Products under Development for Multiple Sclerosis Comparative Analysis, H1 2013 34
Products under Development by Companies, H1 2013 35
Products under Investigation by Universities/Institutes, H1 2013 48
Late Stage Products, H1 2013 51
Mid Clinical Stage Products, H1 2013 52
Early Clinical Stage Products, H1 2013 53
Discovery and Pre-Clinical Stage Products, H1 2013 54
Assessment by Monotherapy Products, H1 2013 205
Assessment by Combination Products, H1 2013 206
Assessment by Route of Administration, H1 2013 207
Assessment by Stage and Route of Administration, H1 2013 208
Assessment by Molecule Type, H1 2013 210
Assessment by Stage and Molecule Type, H1 2013 211

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *